SSY Group's (HKG:2005) Ziprasidone Mesilate obtained registration approval to become a bulk drug for the preparations on the market from China's National Medical Products Administration.
Ziprasidone Mesilate is mainly used to treat acute agitation symptoms in patients with schizophrenia, according to a Wednesday bourse filing.